TOP TEN perturbations for Q8NHB7 (Homo sapiens)

Organism: Homo sapiens
Gene: Q8NHB7
Selected probe(set): 1567288_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q8NHB7 (1567288_at) across 5610 perturbations tested by GENEVESTIGATOR:

HIV-associated neurocognitive disorder study 2 (HIVE) / normal genu sample

Relative Expression (log2-ratio):0.5701432
Number of Samples:2 / 8
Experimental HIV-associated neurocognitive disorder study 2 (HIVE)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). The patients received an antiretroviral therapy (ART).
Control normal genu sample
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from healthy subjects.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):0.5542731
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

HIV-associated neurocognitive disorder study 5 (minimal) / HIV-associated neurocognitive disorder study 4 (minimal)

Relative Expression (log2-ratio):-0.48791456
Number of Samples:6 / 2
Experimental HIV-associated neurocognitive disorder study 5 (minimal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with minimal histopathological changes including trivial microscopic abnormalities, atherosclerosis and minimal perivascular inflammation. The patients received an antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 4 (minimal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with minimal histopathological changes including trivial microscopic abnormalities, atherosclerosis and minimal perivascular inflammation. The patients did not receive any antiretroviral therapy (ART).

HIF-1a depletion study 2 (normoxia; AB81) / control AB81 cell sample (normoxia)

Relative Expression (log2-ratio):0.46053314
Number of Samples:3 / 3
Experimental HIF-1a depletion study 2 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.
Control control AB81 cell sample (normoxia)
Human podocyte cell line AB81 treated with normoxia (20% O2) for 24 hours. Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

bucetin study 2 (300uM) / vehicle (DMSO) treated hepatocyte sample

Relative Expression (log2-ratio):0.43741322
Number of Samples:2 / 2
Experimental bucetin study 2 (300uM)
Hepatocytes treated with compound: bucetin (300uM; CHEMBL1697856) for 24 hours. ATC code:
Control vehicle (DMSO) treated hepatocyte sample
Hepatocytes treated with vehicle (DMSO) for 24 hours.

asthma study 28 / normal alveolar macrophage sample

Relative Expression (log2-ratio):-0.4288311
Number of Samples:15 / 15
Experimental asthma study 28
Alveolar macrophages obtained from patients with asthma by bronchoscopy with bronchoalveolar lavage after pre-treatment with 360mcg albuterol. Macrophages were sorted by flow cytometry using forward scatter and autofluorescence characteristics to 98 ± 2% purity. All subjects had lower lung function than healthy control donors. Subject inclusion criteria: age 18 to 70, non-smokers, a physician diagnosis of asthma, use of only inhaled beta-agonist medications for therapy and at least one of the following: a) asthma symptoms on ≥ 2 days/week, b) beta-agonist use on on ≥ 2 days/week, or c) FEV1 < 85% of predicted. Exclusion criteria: inhaled corticosteroids or leukotriene antagonists use. Subject characteristics: age 35 ± 10 years, FEV1 prebronchodilator 81 ± 15% predicted, FEV1/FVC prebronchodilator 0.7 ± 0.11, FEV1 post-bronchodilator 91 ± 12% predicted, FEV1/FVC post-bronchodilator 0.77 ± 0.09 (mean ± SD), PC20, mg/dl methacholine 0.5 (0.06, 1.2) (median (interquartile range)).
Control normal alveolar macrophage sample
Alveolar macrophages obtained from non-smoking healthy donors by bronchoscopy with bronchoalveolar lavage after pre-treatment with 360mcg albuterol. Macrophages were sorted by flow cytometry using forward scatter and autofluorescence characteristics to 98 ± 2% purity. Subject inclusion criteria: age 30 to 65 years, no history of lung disease and a history of <10 pack-years of smoking with no smoking in the previous 10 years. Subject characteristics: age 41 ± 8 years, FEV1 prebronchodilator 104 ± 12% predicted, FEV1/FVC prebronchodilator 0.80 ± 0.06, FEV1 post-bronchodilator 107 ± 12% predicted, FEV1/FVC post-bronchodilator 0.83 ± 0.05 (mean ± SD), PC20, mg/dl methacholine 64 (64, 64) (median (interquartile range)).

acesulfame K study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):0.41611385
Number of Samples:3 / 7
Experimental acesulfame K study 1 (24h)
HepG2 cells exposed to 2mM acesulfame K in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.

stem cell differentiation study 47 (BMP-2; IBMX; 2d) / stem cell differentiation study 47 (BMP-2; TGFb; 2d)

Relative Expression (log2-ratio):0.41519117
Number of Samples:3 / 3
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 2d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (BMP-2; TGFb; 2d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

polymyositis study 1 / inclusion body myositis study 1

Relative Expression (log2-ratio):0.40656567
Number of Samples:5 / 5
Experimental polymyositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of polymyositis (PM).
Control inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.38886642
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.